Tempus AI (TEM)


Market Price (11/21/2026): $55.02 | Market Cap: $10.0 BilSector: Health Care | Industry: Health Care Technology

Tempus AI (TEM)


Market Price (11/21/2026): $55.02
Market Cap: $10.0 Bil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37%

Megatrend and thematic drivers
Megatrends include Precision Medicine, Biotechnology & Genomics, and Artificial Intelligence. Themes include Personalized Diagnostics, Show more.

Weak multi-year price returns
2Y Excs Rtn is -23%, 3Y Excs Rtn is -30%

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -279 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -18%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7.2%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -10.0%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.1%

Key risks
TEM key risks include [1] substantial net losses and negative cash flow, Show more.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37%
1 Megatrend and thematic drivers
Megatrends include Precision Medicine, Biotechnology & Genomics, and Artificial Intelligence. Themes include Personalized Diagnostics, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -23%, 3Y Excs Rtn is -30%
3 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -279 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -18%
5 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13%
6 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7.2%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -10.0%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.1%
8 Key risks
TEM key risks include [1] substantial net losses and negative cash flow, Show more.

TEM in ETFs

Weight = TEM's share of each fund

VTI0.01%
ITOT0.01%
IWB0.01%
VB0.10%
ARKK5.6%
XOVR1.8%
AGIX1.2%
IBB0.49%
+16 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/20/2026

Nov 20: down 9.3% in one day (S&P 500 down 3.6%)
Tempus AI fell as a broad market selloff deepened amid erupting fear, with nearly everything but Treasuries declining. The sell-off especially impacted AI and chip stocks, which saw a $2.3 trillion weekly wipeout.

Down 36.0% since its Nov 9 high (S&P 500 down 8.4%)
Tempus AI declined over the period as market-wide fear deepened and a sell-off in AI and chip stocks accelerated. Key drops occurred on November 16, when Nvidia tugged the market lower, November 19, as Anthropic hit the market, and November 20.

Nov 2: up 8.7% on its earnings report (S&P 500 down 0.5%)
Tempus AI rose sharply after reporting strong Third Quarter 2026 results before the open, beating earnings and revenue estimates. The company reported earnings of $0.07 per share, surpassing expectations of a loss, with revenue up 23%.

Show more
Prices as of 11/20/2026

Nov 20: down 9.3% in one day (S&P 500 down 3.6%)
Tempus AI fell as a broad market selloff deepened amid erupting fear, with nearly everything but Treasuries declining. The sell-off especially impacted AI and chip stocks, which saw a $2.3 trillion weekly wipeout.

Down 36.0% since its Nov 9 high (S&P 500 down 8.4%)
Tempus AI declined over the period as market-wide fear deepened and a sell-off in AI and chip stocks accelerated. Key drops occurred on November 16, when Nvidia tugged the market lower, November 19, as Anthropic hit the market, and November 20.

Nov 2: up 8.7% on its earnings report (S&P 500 down 0.5%)
Tempus AI rose sharply after reporting strong Third Quarter 2026 results before the open, beating earnings and revenue estimates. The company reported earnings of $0.07 per share, surpassing expectations of a loss, with revenue up 23%.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 23.2% change in TEM stock from 7/31/2026 to 11/20/2026 was primarily driven by a 17.8% change in the company's P/S Multiple.
(LTM values as of)731202611202026Change
Stock Price ($)43.8754.0423.2%
Change Contribution By: 
Total Revenues ($ Mil)1,4321,5095.4%
P/S Multiple5.56.517.8%
Shares Outstanding (Mil)180181-0.8%
Cumulative Contribution23.2%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/20/2026
ReturnCorrelation
TEM23.2% 
Market (SPY)-7.4%43.1%
Sector (XLV)9.5%33.2%

Fundamental Drivers

The -2.6% change in TEM stock from 4/30/2026 to 11/20/2026 was primarily driven by a -16.5% change in the company's P/S Multiple.
(LTM values as of)430202611202026Change
Stock Price ($)55.4854.04-2.6%
Change Contribution By: 
Total Revenues ($ Mil)1,2721,50918.7%
P/S Multiple7.86.5-16.5%
Shares Outstanding (Mil)178181-1.7%
Cumulative Contribution-2.6%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/20/2026
ReturnCorrelation
TEM-2.6% 
Market (SPY)-3.5%42.4%
Sector (XLV)22.4%24.3%

Fundamental Drivers

The -39.9% change in TEM stock from 10/31/2025 to 11/20/2026 was primarily driven by a -60.3% change in the company's P/S Multiple.
(LTM values as of)1031202511202026Change
Stock Price ($)89.8554.04-39.9%
Change Contribution By: 
Total Revenues ($ Mil)9521,50958.5%
P/S Multiple16.46.5-60.3%
Shares Outstanding (Mil)173181-4.4%
Cumulative Contribution-39.9%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/20/2026
ReturnCorrelation
TEM-39.9% 
Market (SPY)2.2%46.8%
Sector (XLV)24.9%25.4%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/20/2026
ReturnCorrelation
TEM  
Market (SPY)71.0%44.8%
Sector (XLV)49.6%30.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
TEM Return----16%75%-8%34%
Peers Return-4%-55%0%34%93%38%53%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
TEM Win Rate---43%58%45% 
Peers Win Rate57%32%43%53%55%62% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
TEM Max Drawdown-----58%-41% 
Peers Max Drawdown-38%-64%-48%-34%-33%-35% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: GH, NTRA, IQV, ILMN, ADPT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/20/2026 (YTD)

How Low Can It Go

EventTEMS&P 500
2025 US Tariff Shock
  % Loss-56.6%-18.8%
  % Gain to Breakeven130.2%23.1%
  Time to Breakeven156 days79 days

Compare to GH, NTRA, IQV, ILMN, ADPT

In The Past

Tempus AI's stock fell -56.6% during the 2025 US Tariff Shock. Such a loss loss requires a 130.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventTEMS&P 500
2025 US Tariff Shock
  % Loss-56.6%-18.8%
  % Gain to Breakeven130.2%23.1%
  Time to Breakeven156 days79 days

Compare to GH, NTRA, IQV, ILMN, ADPT

In The Past

Tempus AI's stock fell -56.6% during the 2025 US Tariff Shock. Such a loss loss requires a 130.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Tempus AI (TEM)

Tempus AI (TEM) is a technology company at the forefront of precision medicine, utilizing artificial intelligence, including generative AI, to create "Intelligent Diagnostics." The company's core mission is to personalize laboratory test results by connecting them to a patient's comprehensive clinical, molecular, and imaging data. This integrated approach aims to guide therapy selection, refine treatment decisions, and explore optimal care pathways, ensuring patients receive highly tailored medical interventions. Tempus achieves this through its proprietary Tempus Platform, which systematically collects and harmonizes multimodal healthcare data from numerous institutions, establishing one of the world's largest libraries of clinical and molecular oncology data.

The company offers a range of products and services built upon its platform, including Next Generation Sequencing (NGS) services, clinical trial matching, and advanced AI Applications. By uniquely straddling the worlds of deep clinical care delivery and leading technology capabilities, Tempus integrates diverse patient information to produce more insightful diagnostic results than traditional labs. Its offerings have gained significant traction, used by over 7,000 physicians across hundreds of provider networks—including more than 65% of all academic medical centers in the United States—and by approximately 95% of the largest public pharmaceutical companies for drug discovery and development.

Initially establishing its business in oncology, which currently represents the majority of its data and revenue, Tempus AI is strategically expanding into other disease areas such as neuropsychiatry, radiology, and cardiology. The company's extensive network of data connections and relationships with healthcare institutions provide it with proprietary access to broad and diverse datasets. This vast data library, significantly larger than major public genomic datasets, forms the critical foundation for training its generative AI models, underpinning Tempus AI's ability to deliver on the promise of personalized, data-driven medicine at scale across multiple therapeutic areas.

AI Analysis | Feedback

Here are 1-3 brief analogies for Tempus AI (TEM):

  1. Tempus AI is like the Tesla of precision medicine, leveraging AI and massive datasets to personalize diagnostics and guide treatment.

  2. Think of Tempus AI as ChatGPT for medical data, using advanced AI to contextualize a patient's unique profile and generate personalized diagnostic insights and treatment paths.

AI Analysis | Feedback

  • Intelligent Diagnostics: AI-enhanced laboratory tests that integrate a patient's clinical data to personalize results and guide therapy selection and treatment decisions across various disease areas.
  • Clinical Next Generation Sequencing (NGS): Genomic sequencing services offered to patients, primarily in oncology, which are made more insightful by connecting results to a patient's personal clinical profile.
  • Clinical Trial Matching Services: Services that leverage integrated multimodal patient data to identify and connect patients with relevant clinical trials.
  • Data De-identification and Structuring Services: Services provided to healthcare institutions for processing, de-identifying, and structuring complex healthcare data.
  • AI Applications (Analytical and Decision Support Capabilities): A product line offering advanced analytics and decision support tools, built upon their extensive data library, to aid physicians and researchers.

AI Analysis | Feedback

Tempus AI (TEM) primarily sells its products and services to other companies and healthcare professionals rather than directly to individuals. Its major customers fall into the following categories:

  1. Pharmaceutical Companies: Tempus AI's offerings have been used by approximately 95% of the largest public pharmaceutical companies (based on 2023 revenue). These companies leverage Tempus AI's data, analytics, and intelligent diagnostics to support drug discovery, development, and therapeutic applications. Specific company names are not provided in the description.

  2. Healthcare Institutions: This category includes hundreds of provider networks and more than 65% of all academic medical centers in the United States. These institutions order Tempus AI's diagnostic products and services (such as Next Generation Sequencing, or NGS), utilize its platform for clinical decision support, and engage in services like clinical trial matching.

  3. Physicians and Researchers: These professionals, often operating within the aforementioned healthcare institutions and pharmaceutical companies, are direct users and beneficiaries of Tempus AI's intelligent diagnostics and AI applications. They use the platform to make personalized, data-driven decisions to improve patient care and accelerate drug discovery and development.

AI Analysis | Feedback

null

AI Analysis | Feedback

Eric Lefkofsky, Founder & Chief Executive Officer

Eric Lefkofsky is the Founder and CEO of Tempus AI. A serial entrepreneur, he co-founded several successful companies before Tempus, including Groupon, Mediaocean, Echo Global Logistics, and InnerWorkings. He also serves as a co-managing partner of Lightbank, a venture capital firm. Lefkofsky founded Tempus AI in 2015, driven by a personal mission to improve patient outcomes through data-driven solutions, after his wife's breast cancer diagnosis.

James Rogers, Chief Financial Officer

James Rogers has served as Tempus AI's Chief Financial Officer since April 2021. He joined Tempus in 2017 as the first finance hire, building the finance function and helping guide the company through its public offering. Prior to Tempus, he held various finance positions at Groupon, including leading Financial Planning & Analysis (FP&A) for the North America business and serving as the financial controller of Asia Pacific operations. Rogers began his career in audit at Ernst & Young.

Ryan Fukushima, Chief Operating Officer

Ryan Fukushima has been the Chief Operating Officer at Tempus AI since September 2015 and was part of the founding team. He is also a co-founder and currently serves as CEO and a director of Pathos AI, Inc. Before joining Tempus, Fukushima was an Entrepreneur-in-Residence and Vice President at Lightbank LLC, a venture fund. He also worked at Hyde Park Venture Partners and as an engineer for Cisco and VMware.

Shane Colley, Chief Technology Officer

Shane Colley is the Chief Technology Officer at Tempus AI. Before joining Tempus, Colley was the Vice President of Research and Development at R1 RCM (formerly Accretive Health), where he was responsible for building and leading a global organization of over 200 professionals focused on R1's technology portfolio.

Ezra Cohen, MD, Chief Medical Officer of Oncology

Dr. Ezra Cohen joined Tempus AI in May 2023 as the Chief Medical Officer of Oncology. He is a prominent medical oncologist and cancer researcher with extensive clinical and research experience. Prior to his role at Tempus, Dr. Cohen served as the Chief of the Division of Hematology-Oncology and the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. He also spent 15 years at the University of Chicago, where he co-directed the Head and Neck Cancer Program.

AI Analysis | Feedback

Key Risks to Tempus AI (TEM)

  • Regulatory and Data Privacy Compliance: Tempus AI operates in a highly regulated healthcare environment, necessitating strict adherence to data privacy laws such as HIPAA in the United States. The company's business model relies heavily on acquiring and processing sensitive patient data, both as a covered entity and a business associate. Non-compliance, data breaches, or evolving regulatory landscapes (including those specific to AI in healthcare) could lead to significant legal penalties, reputational damage, and operational restrictions on their ability to collect and utilize data.
  • Dependence on Data Acquisition and Healthcare Institution Partnerships: Tempus AI's core "Intelligent Diagnostics" and AI models are built upon one of the largest libraries of clinical and molecular oncology data, amassed through approximately 450 unique data connections with over 2,000 healthcare institutions. The company's continued success is fundamentally reliant on establishing and maintaining these data pipelines and strategic partnerships. Any disruption to these critical relationships, challenges in securing new data agreements, or increased costs associated with data acquisition and integration could severely impair its ability to grow its proprietary dataset, develop and train its generative AI models, and deliver its products and services.
  • Efficacy, Clinical Adoption, and Competition in AI-Powered Diagnostics: The company's value proposition centers on leveraging AI, including generative AI, to create more accurate and personalized diagnostic tests. There is an inherent risk that the AI models may not consistently achieve the anticipated accuracy or clinical utility, or that they may face challenges in widespread adoption by physicians and healthcare systems. Furthermore, the market for AI in healthcare and diagnostics is becoming increasingly competitive, with both established corporations and agile startups vying for market share. Tempus AI must continuously innovate and demonstrate tangible benefits to distinguish its offerings and secure market penetration amidst this competitive pressure.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Tempus AI (TEM)

Tempus AI (TEM) is expected to drive future revenue growth over the next 2-3 years through several key initiatives, focusing on its core diagnostics business, advanced AI capabilities, and strategic market expansion:

  1. Growth in Diagnostics Volume, particularly in Oncology and Hereditary Testing: Tempus AI anticipates continued strong growth in the volume of its diagnostic tests, especially within oncology and hereditary testing. The company reported a 29% increase in oncology unit volume and a 23% increase in hereditary testing in Q4 2025, with similar momentum expected to continue. This growth is supported by increasing adoption of genomic sequencing in cancer care and the expansion of Tempus's comprehensive test portfolio.
  2. Increased Average Selling Prices (ASPs) and Improved Reimbursement: A significant driver of revenue growth is the projected increase in average selling prices (ASPs) for Tempus's diagnostic tests. Management expects substantial ASP upside, with an outline of more than $500 per test of potential ASP improvement over time. This improvement is largely attributed to the transition of volume from lab-developed tests to FDA-approved versions, such as the xT CDx, which is priced at $4,500 compared to the previous $1,630-$2,200 range for its primary oncology test. Additionally, the company anticipates that continued FDA approvals and the shift of tests into Advanced Diagnostic Laboratory Test (ADLT) status will help improve reimbursement rates.
  3. Expansion and Monetization of Data and AI Capabilities: The "Data and Services" or "Insights" segment is a rapidly scaling, high-margin revenue stream for Tempus AI. This segment, which includes data licensing and AI algorithm commercialization, delivered 69% reported revenue growth in Q4 2025 (including a one-time warrant impact) and is projected to grow by roughly 40% in the following quarter. Tempus has a strong commercial pipeline, with total contract value exceeding $1.1 billion, providing significant visibility into future data-driven expansion. Strategic collaborations, such as multi-year agreements to build multimodal foundation models in oncology, are also contributing to this segment's growth.
  4. Launch of New Diagnostic Products and Expansion into New Disease Areas: While oncology remains a primary focus, Tempus AI is expanding its diagnostic offerings and entering new disease areas. The company has launched new liquid biopsy assays like xM for Treatment Response Monitoring ("TRM") and expects the xF liquid biopsy FDA submission to have a significant impact on revenue starting in 2027. The background also mentions expansion into neuropsychiatry, radiology, and cardiology, indicating a broader market reach for its Intelligent Diagnostics.

AI Analysis | Feedback

Capital Expenditures

  • Capital expenditures have primarily focused on the development and expansion of the Tempus Platform, which includes proprietary software and the establishment of a network of approximately 450 unique data connections across more than 2,000 healthcare institutions.
  • Significant investment has been directed towards building and maintaining a unified multimodal database and cloud infrastructure, which now houses over 200 petabytes of data, serving as a proprietary training dataset for generative AI applications.
  • The company has also focused capital on expanding its Intelligent Diagnostics and AI applications beyond oncology into new disease areas such as neuropsychiatry, radiology, and cardiology, by leveraging large amounts of de-identified data.

Better Bets vs. Tempus AI (TEM)

Peer Outperformance in Health Care Technology

TEM has outperformed 55% of its 33 Health Care Technology peers over 1Y. Health Care Technology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Health Care Technology constituents that TEM has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
55%
of 33 industry peers · -17.7% return
3Y
—
insufficient price history
5Y
—
insufficient price history
No Health Care Technology peer with a comparable growth profile has beaten TEM by more than 20pp over 1Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Technology is TEM's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 17.3%74.7%198.5% CAH 523% · MCK 396% · COR 198%
Health Care Services 20 30.7%20.5%14.0% RDNT 146% · HIMS 100% · DGX 92%
Managed Health Care 8 60.1%-12.7%-9.2% OSCR 140% · HQY 54% · ELV 2%
Health Care Facilities 26 13.2%13.0%-10.4% THC 240% · NHC 211% · EHC 187%
Health Care Equipment 50 -2.1%6.7%-19.0% GKOS 393% · UFPT 319% · TMDX 274%
Health Care Supplies 11 19.9%-4.3%-41.8% LNTH 256% · HAE 114% · MMSI 22%
Pharmaceuticals 61 -16.1%-0.2%-42.0% LQDA 1178% · KNSA 670% · XERS 648%
Life Sciences Tools & Services 110 -25.7%-28.8%-76.5% AXGN 471% · MEDP 169% · NTRA 165%
Biotechnology 370 -35.9%-45.4%-85.2% ELVN 1310% · DNTH 1164% · TRVI 1159%
Health Care Technology ← 23 -26.4%-56.9%-86.5% VEEV -13% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

TEMGHNTRAIQVILMNADPTMedian
NameTempus AIGuardant.Natera IQVIA Illumina Adaptive. 
Mkt Price55.02145.81274.17247.00195.0027.85170.41
Mkt Cap10.019.639.540.729.44.524.5
Rev LTM1,5091,2792,90917,3114,5382982,209
Op Inc LTM-279-504-2602,393970-48-154
FCF LTM-151-232322,0791,057-912
FCF 3Y Avg-202-256272,084868-62-17
CFO LTM-108-1732132,7361,230-4104
CFO 3Y Avg-173-2171442,7061,016-5843

Growth & Margins

TEMGHNTRAIQVILMNADPTMedian
NameTempus AIGuardant.Natera IQVIA Illumina Adaptive. 
Rev Chg LTM36.6%41.7%37.4%8.8%5.8%17.9%27.2%
Rev Chg 3Y Avg47.1%33.8%43.5%5.3%0.6%19.7%26.7%
Rev Chg Q23.1%36.1%34.1%8.0%4.2%-10.7%15.6%
QoQ Delta Rev Chg LTM5.4%8.1%7.5%1.9%1.0%-3.3%3.7%
Op Inc Chg LTM-15.2%-13.9%26.0%6.0%21.6%38.3%13.8%
Op Inc Chg 3Y Avg-64.1%-0.1%10.9%7.4%160.0%35.3%9.1%
Op Mgn LTM-18.5%-39.4%-9.0%13.8%21.4%-16.2%-12.6%
Op Mgn 3Y Avg-49.5%-54.3%-13.8%14.1%15.1%-47.1%-30.5%
QoQ Delta Op Mgn LTM1.3%0.3%1.7%-0.1%1.5%-4.0%0.8%
CFO/Rev LTM-7.2%-13.6%7.3%15.8%27.1%-1.4%2.9%
CFO/Rev 3Y Avg-18.9%-25.0%6.0%16.8%23.0%-29.1%-6.4%
FCF/Rev LTM-10.0%-18.2%1.1%12.0%23.3%-3.0%-0.9%
FCF/Rev 3Y Avg-21.6%-28.9%0.9%12.9%19.7%-30.8%-10.4%

Valuation

TEMGHNTRAIQVILMNADPTMedian
NameTempus AIGuardant.Natera IQVIA Illumina Adaptive. 
Mkt Cap10.019.639.540.729.44.524.5
P/S6.615.313.62.46.515.010.1
P/Op Inc-35.8-38.9-151.717.030.4-92.7-37.3
P/EBIT-72.9-40.8-178.517.425.5-72.4-56.6
P/E-52.7-40.4-239.829.232.9-63.3-46.6
P/CFO-92.0-113.0185.614.923.9-1,044.5-38.6
Total Yield-1.9%-2.5%-0.4%3.4%3.1%-1.6%-1.0%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-1.7%-4.7%0.1%5.4%4.0%-6.0%-0.8%
D/E0.10.10.00.40.10.10.1
Net D/E0.10.0-0.00.30.00.00.0

Returns

TEMGHNTRAIQVILMNADPTMedian
NameTempus AIGuardant.Natera IQVIA Illumina Adaptive. 
1M Rtn-18.8%-12.5%-33.7%-10.7%-31.1%9.9%-15.7%
3M Rtn-24.3%-14.6%-17.4%-4.9%-11.1%7.2%-12.8%
6M Rtn19.1%22.6%34.9%47.1%35.0%100.6%35.0%
12M Rtn-16.2%45.4%21.6%13.8%63.5%70.6%33.5%
3Y Rtn36.7%536.2%408.2%19.1%109.1%560.0%258.6%
1M Excs Rtn-10.5%-7.3%-28.5%-8.0%-24.4%17.3%-9.3%
3M Excs Rtn-13.7%-7.6%-13.2%-2.0%-9.5%12.1%-8.5%
6M Excs Rtn19.9%23.3%35.7%47.9%35.8%101.4%35.7%
12M Excs Rtn-32.2%34.8%13.9%1.9%50.5%72.2%24.3%
3Y Excs Rtn-29.2%474.3%352.7%-45.0%34.9%486.2%193.8%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Single Segment1,272693   
Data and services  16912363
Genomics  363198195
Total1,272693532321258


Price Behavior

Price Behavior
Market Price$54.04 
Market Cap ($ Bil)9.8 
First Trading Date06/14/2024 
Distance from 52W High-36.5% 
   50 Days200 Days
DMA Price$72.79$57.58
DMA Trendupup
Distance from DMA-25.8%-6.1%
 3M1YR
Volatility88.4%77.7%
Downside Capture275.00285.68
Upside Capture266.75244.09
Correlation (S&P 500)41.4%44.2%
TEM Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta3.182.893.052.552.61-0.02
Up Beta3.634.460.431.782.11-0.31
Down Beta4.124.182.632.282.430.24
Up Capture183%313%694%467%544%6611%
Bmk +ve Days12182862130427
Stock +ve Days12223260114295
Down Capture313%140%196%203%174%113%
Bmk -ve Days10253664121325
Stock -ve Days10213266137300

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TEM
TEM-21.9%77.7%0.01-
Sector ETF (XLV)18.4%17.1%0.8026.7%
Equity (SPY)5.2%14.4%0.1146.1%
Gold (GLD)-13.9%29.3%-0.5227.7%
Commodities (DBC)28.2%21.5%1.05-5.8%
Real Estate (VNQ)8.6%14.3%0.3313.3%
Bitcoin (BTCUSD)-32.4%43.7%-0.7832.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TEM
TEM6.5%97.2%0.56-
Sector ETF (XLV)7.5%15.4%0.2930.3%
Equity (SPY)9.6%17.4%0.3944.8%
Gold (GLD)13.1%19.3%0.5312.7%
Commodities (DBC)6.6%19.6%0.22-0.5%
Real Estate (VNQ)0.5%19.0%-0.0825.3%
Bitcoin (BTCUSD)-0.7%51.4%0.1728.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TEM
TEM3.2%97.2%0.56-
Sector ETF (XLV)11.4%16.8%0.5530.3%
Equity (SPY)14.1%18.1%0.6644.8%
Gold (GLD)10.4%16.6%0.5012.7%
Commodities (DBC)7.2%18.2%0.31-0.5%
Real Estate (VNQ)5.9%20.7%0.2425.3%
Bitcoin (BTCUSD)56.2%66.3%0.9628.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity24.5 Mil
Short Interest: % Change Since 10152026-3.3%
Average Daily Volume5.5 Mil
Days-to-Cover Short Interest4.5 days
Basic Shares Quantity181.3 Mil
Short % of Basic Shares13.5%

Earnings Returns History

Updated 11/11/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/2/20268.7%5.3% 
7/30/2026-0.9%4.1%44.6%
5/5/2026-1.1%-13.2%-3.3%
2/24/2026-7.3%-11.3%-19.3%
11/4/2025-2.6%-15.3%-9.3%
8/8/20253.6%21.9%36.6%
5/6/202512.6%32.0%12.4%
2/24/2025-15.0%-26.8%-15.8%
...
SUMMARY STATS   
# Positive365
# Negative744
Median Positive8.7%13.6%36.6%
Median Negative-4.5%-14.2%-12.5%
Max Positive12.6%56.8%44.6%
Max Negative-15.0%-26.8%-19.3%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/2/20268.7%5.3% 
7/30/2026-0.9%4.1%44.6%
5/5/2026-1.1%-13.2%-3.3%
2/24/2026-7.3%-11.3%-19.3%
11/4/2025-2.6%-15.3%-9.3%
8/8/20253.6%21.9%36.6%
5/6/202512.6%32.0%12.4%
2/24/2025-15.0%-26.8%-15.8%
11/4/2024-10.1%56.8%17.2%
8/6/2024-4.5%4.9%36.9%
SUMMARY STATS   
# Positive365
# Negative744
Median Positive8.7%13.6%36.6%
Median Negative-4.5%-14.2%-12.5%
Max Positive12.6%56.8%44.6%
Max Negative-15.0%-26.8%-19.3%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/02/202610-Q
06/30/202607/30/202610-Q
03/31/202605/05/202610-Q
12/31/202502/24/202610-K
09/30/202511/04/202510-Q
06/30/202508/08/202510-Q
03/31/202505/06/202510-Q
12/31/202402/24/202510-K
09/30/202411/04/202410-Q
06/30/202408/06/202410-Q
03/31/202406/17/2024424B4
09/30/202312/15/2023DRS/A
09/30/202201/17/2023DRS/A
09/30/202112/03/2021DRS/A
06/30/202110/28/2021DRS/A
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/02/202610-Q
06/30/202607/30/202610-Q
03/31/202605/05/202610-Q
12/31/202502/24/202610-K
09/30/202511/04/202510-Q
06/30/202508/08/202510-Q
03/31/202505/06/202510-Q
12/31/202402/24/202510-K
09/30/202411/04/202410-Q
06/30/202408/06/202410-Q
03/31/202406/17/2024424B4
09/30/202312/15/2023DRS/A
09/30/202201/17/2023DRS/A
09/30/202112/03/2021DRS/A
06/30/202110/28/2021DRS/A

Recent Forward Guidance

Updated 11/3/2026

Latest: Q3 2026 Earnings Reported 11/2/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.60 Bil1.60 Bil1.60 Bil0.2% RaisedGuidance: 1.60 Bil for 2026
2026 Revenue GrowthReported 25.0%    
2026 Adjusted EBITDAReported 65.00 Mil 0.0% AffirmedGuidance: 65.00 Mil for 2026


Prior: Q2 2026 Earnings Reported 7/30/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.59 Bil1.60 Bil1.60 Bil0.3% RaisedGuidance: 1.59 Bil for 2026
2026 Adjusted EBITDAReported 65.00 Mil 0 AffirmedGuidance: 65.00 Mil for 2026

Q1 2026 Earnings Reported 5/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.59 Bil1.59 Bil1.60 Bil0.3% RaisedGuidance: 1.59 Bil for 2026
2026 Adjusted EBITDAReported 65.00 Mil 0 AffirmedGuidance: 65.00 Mil for 2026

Q4 2025 Earnings Reported 2/24/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported 1.59 Bil 25.7% Higher NewActual: 1.26 Bil for 2025
2026 Revenue GrowthReported 25.0%  -55.0%Lower NewActual: 80.0% for 2025
2026 Adjusted EBITDAReported 65.00 Mil    

Insider Activity

Updated 11/19/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Polovin, AndrewEVP, Chief Legal OfficerDirectSell1119202663.026,704422,4608,096,629Form
2Lefkofsky, Eric PCEO and ChairmanDirectSell1119202663.0217,0741,075,930131,139,132Form
3Rogers, James WilliamChief Financial OfficerDirectSell1119202663.027,079446,0886,235,083Form
4Fukushima, RyanCEO, DataDirectSell1119202663.0210,247645,72041,099,742Form
5Bartolucci, Ryan MChief Accounting OfficerDirectSell1119202663.021,54097,0453,734,612Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Polovin, AndrewEVP, Chief Legal OfficerDirectSell1119202663.026,704422,4608,096,629Form
2Lefkofsky, Eric PCEO and ChairmanDirectSell1119202663.0217,0741,075,930131,139,132Form
3Rogers, James WilliamChief Financial OfficerDirectSell1119202663.027,079446,0886,235,083Form
4Fukushima, RyanCEO, DataDirectSell1119202663.0210,247645,72041,099,742Form
5Bartolucci, Ryan MChief Accounting OfficerDirectSell1119202663.021,54097,0453,734,612Form
6Epstein, David RDirectSell1104202674.2937027,4872,263,913Form
7Fukushima, RyanCEO, DataSpouseSell1104202674.29805,9431,173,336Form
8Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell1029202670.3657,5004,045,725597,204,068Form
9Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell1029202670.36135,0009,498,1281,035,328,998Form
10Lefkofsky, Eric PCEO and ChairmanLefkofsky Family FoundationSell1029202670.437,500528,19655,962,743Form
11Lefkofsky, Eric PCEO and ChairmanVas.org FoundationSell1029202670.3550,0003,517,5883,517,588Form
12Schoenherr, Thomas EdwardCEO, DiagnosticsDirectSell929202685.0010,281873,8856,522,900Form
13Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell924202677.4757,5004,454,323661,973,066Form
14Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell924202677.47135,00010,458,0031,150,416,635Form
15Lefkofsky, Eric PCEO and ChairmanLefkofsky Family FoundationSell924202677.467,500580,98362,136,642Form
16Lefkofsky, Eric PCEO and ChairmanVas.org FoundationSell924202677.4750,0003,873,3207,746,641Form
17Bartolucci, Ryan MChief Accounting OfficerDirectSell918202675.007,062529,6504,560,300Form
18Polovin, AndrewEVP, Chief Legal OfficerDirectSell918202675.002,951221,32510,139,175Form
19Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell918202680.5757,5004,632,717693,117,540Form
20Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell918202680.57135,00010,876,8171,207,364,488Form
21Lefkofsky, Eric PCEO and ChairmanLefkofsky Family FoundationSell918202680.577,500604,26865,231,176Form
22Fukushima, RyanCEO, DataSpouseSell918202670.0070049,0001,111,180Form
23Fukushima, RyanCEO, DataSpouseSell903202662.7130,8461,934,2441,039,297Form
24Doudna, Jennifer ADirectSell903202665.5567644,3121,656,186Form
25Epstein, David RDirectSell903202665.5525016,3882,021,824Form
26West, NadjaDirectSell901202669.003,000207,0002,206,689Form
27Lefkofsky, Eric PCEO and ChairmanVas.org FoundationSell827202669.8711,848827,85710,480,966Form
28Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell827202668.4657,5003,936,377592,872,040Form
29Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell827202668.46135,0009,241,7811,035,111,592Form
30Lefkofsky, Eric PCEO and ChairmanLefkofsky Family FoundationSell827202668.447,500513,31455,925,958Form
31Lefkofsky, Eric PCEO and ChairmanVas.org FoundationSell827202668.0238,1522,595,14011,009,075Form
32Schoenherr, Thomas EdwardCEO, DiagnosticsDirectSell825202670.002,694188,5806,091,470Form
33Fukushima, RyanCEO, DataSpouseSell825202670.0014,2861,000,0203,319,400Form
34Schoenherr, Thomas EdwardCEO, DiagnosticsDirectSell820202658.408,082471,9915,239,380Form
35Rogers, James WilliamChief Financial OfficerDirectSell820202660.0026,3131,578,7806,361,440Form
36Polovin, AndrewEVP, Chief Legal OfficerDirectSell820202656.007,927443,9127,735,840Form
37Schoenherr, Thomas EdwardCEO, DiagnosticsDirectSell820202649.619,232458,0004,851,709Form
38Rogers, James WilliamChief Financial OfficerDirectSell820202649.6122,5291,117,6646,565,239Form
39Fukushima, RyanCEO, DataDirectSell820202649.6141,0952,038,72327,903,789Form
40Polovin, AndrewEVP, Chief Legal OfficerDirectSell820202649.6122,1481,098,7627,246,384Form
41Bartolucci, Ryan MChief Accounting OfficerDirectSell820202649.616,175306,3423,366,832Form
42Lefkofsky, Eric PCEO and ChairmanDirectSell820202649.61132,5916,577,840104,088,229Form
43West, NadjaDirectSell818202653.903,000161,7001,885,476Form
44Fukushima, RyanCEO, DataSpouseSell811202650.0420,0001,000,8006,202,208Form
45Fukushima, RyanCEO, DataSpouseSell805202646.1923,8181,100,0766,648,353Form
46Epstein, David RDirectSell805202643.4037016,0581,349,480Form
47Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell730202642.0657,5002,418,431366,667,003Form
48Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell730202642.06135,0005,678,053641,639,753Form
49Lefkofsky, Eric PCEO and ChairmanLefkofsky Family FoundationSell730202642.067,500315,44634,683,584Form
50Lefkofsky, Eric PCEO and ChairmanVas.org FoundationSell730202642.0650,0002,102,9848,411,937Form
51Fukushima, RyanCEO, DataSpouseSell710202657.3933,2841,910,1239,627,687Form
52Fukushima, RyanCEO, DataSpouseSell708202660.0010,000600,00012,062,820Form
53Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell701202657.4833,2501,911,278504,421,147Form
54Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell701202657.48133,0007,645,111884,675,556Form
55Doudna, Jennifer ADirectSell629202655.002,673147,0151,426,810Form
56Rogers, James WilliamChief Financial OfficerDirectSell629202655.0011,529634,0956,317,630Form
57Epstein, David RDirectSell603202649.4025012,3501,554,322Form
58Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell529202646.7033,2501,552,661411,328,412Form
59Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell529202646.70133,0006,210,651724,893,582Form
60Schoenherr, Thomas EdwardCEO, DiagnosticsDirectSell521202644.071,58069,6314,716,768Form
61Rogers, James WilliamChief Financial OfficerDirectSell521202644.0710,853478,2925,570,228Form
62Lefkofsky, Eric PCEO and ChairmanDirectSell521202644.0722,335984,30398,307,874Form
63Fukushima, RyanCEO, DataDirectSell521202644.0713,550597,14826,598,801Form
64Polovin, AndrewEVP, Chief Legal OfficerDirectSell521202644.078,703383,5415,650,435Form
65Bartolucci, Ryan MChief Accounting OfficerDirectSell521202644.074,116181,3923,262,987Form
66Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell430202651.1333,2501,700,124452,093,953Form
67Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell430202651.13133,0006,800,499800,539,898Form
68Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell327202646.3833,2501,542,232411,649,930Form
69Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell327202646.38133,0006,168,918732,360,468Form
70Epstein, David RDirectSell304202650.6925012,6721,307,853Form
71Rogers, James WilliamChief Financial OfficerDirectSell304202650.6911,414578,5766,450,201Form
72Polovin, AndrewEVP, Chief Legal OfficerDirectSell220202660.3110,949660,2927,653,932Form
73Phelps, ErikEVP, Chief Admin. OfficerDirectSell220202659.439,464562,4724,743,692Form
74Bartolucci, Ryan MChief Accounting OfficerDirectSell220202659.052,902171,3632,430,439Form
75Polovin, AndrewEVP, Chief Legal OfficerDirectSell220202659.058,143480,8445,872,345Form
76Fukushima, RyanChief Executive Officer, DataDirectSell220202659.059,592566,40841,001,604Form
77Rogers, James WilliamChief Financial OfficerDirectSell220202659.0510,084595,4605,973,852Form
78Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell220202658.8733,2501,957,446524,435,636Form
79Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell220202658.87133,0007,830,159937,409,521Form
80Lefkofsky, Eric PCEO and ChairmanDirectSell220202659.0513,587802,312117,487,415Form
81Epstein, David RDirectSell204202659.4137021,9821,547,690Form
82Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell130202665.5633,2502,179,835586,197,451Form
83Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell130202665.56133,0008,719,3721,052,583,498Form
84Fukushima, RyanChief Operating OfficerSpouseSell107202664.265,000321,3009,562,402Form
85Doudna, Jennifer ADirectSell106202660.171,25075,2121,365,979Form
86Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell1222202563.9933,2502,127,643574,289,789Form
87Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell1222202563.99133,0008,510,8351,035,920,178Form
88Phelps, ErikEVP & Chief Admin & Legal OffDirectSell1218202567.421,30287,7816,019,258Form
89Rogers, James WilliamChief Financial OfficerDirectSell1212202573.2019,9661,461,4798,143,322Form
90Frederick, Wayne AIDirectSell1209202577.233,675283,8201,918,084Form
91Epstein, David RDirectSell1203202575.5525018,8881,996,107Form
92Fukushima, RyanChief Operating OfficerSpouseSell1203202575.725,000378,62011,646,969Form
93Doudna, Jennifer ADirectSell1203202575.5567651,0721,809,574Form
94Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell1125202574.1033,2502,463,825667,495,245Form
95Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell1125202574.10133,0009,855,3001,227,945,853Form
96Polovin, AndrewEVP and General CounselDirectSell1125202575.0012,874965,5508,069,250Form
97Lefkofsky, Eric PCEO and ChairmanGray Media, LLCSell1120202568.9733,2502,293,217623,567,731Form
98Lefkofsky, Eric PCEO and ChairmanBlue Media, LLCSell1120202568.97133,0009,172,8821,152,091,134Form
99Polovin, AndrewEVP and General CounselDirectSell1120202568.066,387434,7078,198,931Form
100Lefkofsky, Eric PCEO and ChairmanDirectSell1120202565.5416,8291,102,944131,287,135Form
101Rogers, James WilliamChief Financial OfficerDirectSell1120202565.547,257475,6118,599,670Form
102Polovin, AndrewEVP and General CounselDirectSell1120202565.545,205341,1268,313,586Form
103Phelps, ErikEVP & Chief Admin & Legal OffDirectSell1120202565.543,533231,5475,936,596Form
104Fukushima, RyanChief Operating OfficerDirectSell1120202565.5410,099661,87054,336,492Form
105Bartolucci, Ryan MChief Accounting OfficerDirectSell1120202565.541,834120,1972,887,673Form
106Doudna, Jennifer ADirectSell1113202571.451,926137,6131,759,671Form
107Fukushima, RyanChief Operating OfficerSpouseSell1105202589.035,000445,16011,129,000Form
108Epstein, David RDirectSell1105202590.0037033,3002,400,390Form

Investor Activity (13F)

Updated Nov 21, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
GC Wealth Management RIA, LLC$299.0 Mil12.4%512Hold13F
Eagle Health Investments LP$11.6 Mil2.4%26New13F
KADENSA CAPITAL Ltd$16.8 Mil2.3%39Hold13F
Softbank Group Corp.$244.4 Mil2.1%31Hold13F
Alphabet Inc.$70.1 Mil1.7%27Hold13F
Lingotto Investment Management LLP$64.0 Mil1.3%34ADD +23.8%13F
Casdin Capital, LLC$13.3 Mil1.0%40Hold13F
Patient Capital Management, LLC$20.0 Mil0.7%38ADD +15.7%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Eagle Health Investments LP$11.6 Mil2.4%26New13F
Lingotto Investment Management LLP$64.0 Mil1.3%34ADD +23.8%13F
Patient Capital Management, LLC$20.0 Mil0.7%38ADD +15.7%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
GC Wealth Management RIA, LLC$299.0 Mil12.4%512Hold13F
Softbank Group Corp.$244.4 Mil2.1%31Hold13F
Alphabet Inc.$70.1 Mil1.7%27Hold13F
Lingotto Investment Management LLP$64.0 Mil1.3%34ADD +23.8%13F
Patient Capital Management, LLC$20.0 Mil0.7%38ADD +15.7%13F
KADENSA CAPITAL Ltd$16.8 Mil2.3%39Hold13F
Casdin Capital, LLC$13.3 Mil1.0%40Hold13F
Eagle Health Investments LP$11.6 Mil2.4%26New13F
Core Cache Last Updated: 11/20/2026